In a challenging year for the biotech sector, Fulgent Genetics Inc . (NASDAQ:FLGT) stock has touched a 52-week low, dipping to $16.54. The company, known for its comprehensive genetic testing solutions, has faced a significant downturn, with its stock price reflecting a 1-year change of -35.25%. According to InvestingPro data, the company maintains a strong financial position with a healthy current ratio of 4.41 and more cash than debt on its balance sheet. Investors are closely monitoring Fulgent Genetics as it navigates through a period marked by volatility and investor caution. While not currently profitable, InvestingPro analysis indicates the company is expected to return to profitability this year, with analyst targets ranging from $22 to $30. Management’s aggressive share buyback program and the company’s innovative approach to genetic diagnostics suggest potential for a market valuation rebound. For deeper insights and additional ProTips, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Fulgent Genetics disclosed its third-quarter earnings for 2024, revealing a total revenue of $71.7 million, a decrease from the previous year’s $84.7 million. This decline is linked to the diminished revenue from COVID-19 testing. However, the firm experienced an 18.8% year-over-year rise in precision diagnostics revenue, particularly in reproductive health and oncology. The company also updated its progress on drug candidates FID-007 and FID-022, with the former entering Phase II clinical trials and the latter progressing towards an investigational new drug application by year-end.
Fulgent Genetics reported a decrease in operating expenses to $43.9 million and a $10.1 million impairment loss on its investment in Helio (WA:HEL) Health. The company’s core revenue projection for 2024 stands at $280 million, reflecting a 7% year-over-year growth, and an anticipated EPS loss of $1.70, excluding one-time charges. Notably, Fulgent secured a $99 million VA contract, expected to contribute to revenue growth starting in 2025.
During the earnings call, management expressed confidence in their growth strategy in the anatomic pathology segment and confirmed no additional operating expenses are anticipated for servicing the recent VA contract. These are some of the recent developments at Fulgent Genetics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.